Compounders Research Compare

Prime Medicine, Inc.(PRME)

Biotechnology · Cambridge, MA

$3.52+0.31 (+9.78%)

Delayed quote: Oct 6, 2026, 3:35 PM EDT

About Prime Medicine, Inc.

Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.

Cambridge, MA

146 employees

www.primemedicine.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Allan Reine

View full financials

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T19:37:56.778Z.

Stored calculation inputs

Calculation as of: 2026-10-06T19:37:56.778Z.

Quote observation: 2026-10-06T19:35:20.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 636,495,894
Total debt · period ending 2026-06-30: 112,478,000
Cash · period ending 2026-06-30: 47,451,000
TTM operating EBITDA · period ending 2026-06-30: -189,122,000

FMP input reference: ed0d84ebe65fc765338e7baf7154c4548c52c7814b601df66b93f049f622236d

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

PRME EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

PRME Competitors' EV/EBITDA Ratio

Prime Medicine, Inc.

Current

Market Cap

$636.50M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Aura Biosciences, Inc.

Market Cap

$631.48M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MiMedx Group, Inc.

Market Cap

$660.28M

EV/EBITDA Ratio

25.77x

TTM Avg

12.95x

3Y Avg

19.43x

5Y Avg

199.83x

Zevra Therapeutics, Inc.

Market Cap

$630.76M

EV/EBITDA Ratio

12.02x

TTM Avg

14.05x

3Y Avg

14.05x

5Y Avg

17.93x

Starling Oncology, Inc.

Market Cap

$658.89M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Helus Pharma Inc.

Market Cap

$659.51M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

4D Molecular Therapeutics, Inc.

Market Cap

$660.25M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OmniAb, Inc.

Market Cap

$621.21M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SOPHiA GENETICS S.A.

Market Cap

$620.82M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Annexon, Inc.

Market Cap

$665.12M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Prime Medicine, Inc. (PRME)	$636.50M	N/A	N/A	N/A	N/A
Aura Biosciences, Inc. (AURA)vs ›	$631.48M	N/A	N/A	N/A	N/A
MiMedx Group, Inc. (MDXG)vs ›	$660.28M	25.77x	12.95x	19.43x	199.83x
Zevra Therapeutics, Inc. (ZVRA)vs ›	$630.76M	12.02x	14.05x	14.05x	17.93x
Starling Oncology, Inc. (STLN)vs ›	$658.89M	N/A	N/A	N/A	N/A
Helus Pharma Inc. (HELP)vs ›	$659.51M	N/A	N/A	N/A	N/A
4D Molecular Therapeutics, Inc. (FDMT)vs ›	$660.25M	N/A	N/A	N/A	N/A
OmniAb, Inc. (OABI)vs ›	$621.21M	N/A	N/A	N/A	N/A
SOPHiA GENETICS S.A. (SOPH)vs ›	$620.82M	N/A	N/A	N/A	N/A
Annexon, Inc. (ANNX)vs ›	$665.12M	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics